Very positive story today from Quidel's CEO on the new product platforms and the fact they have high margins compared to Quidel's older product lines, and they are selling better than expected with the majority of sales to new customers for both physician offices and hospitals Large potential market for Sofia has "barely been scratched" according to the CEO. Amplivue sales also well ahead of projected sales for C. diff toxin test, and management "extremely pleased" about initial reception of test in this quarter. Second generation C. diff test to be released this fall with even more "cool" features. 2015 projections for new revenue to be discussed on Thursday (for these new higher margin products). Analyst day presentation on Thursday to explain why these new tests are likely to be competitive and have continued rapid adoption. Wedbush analyst has set up those who shorted yesterday on his downgrade for a possible short squeeze after the presentation on Thursday this week.